Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation.

Slides:

Advertisements

Similar presentations

Prognostic Value of Total Bilirubin in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Coronary Intervention Mehmet.

Advertisements

Figure 1 Flow diagram displaying the proportions of patients with troponin measurements available from all eligible patients and the resulting study population.

Copyright © 2006 American Medical Association. All rights reserved.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Circ Cardiovasc Interv

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Comparison between Kaplan-Meier survival estimates of Bristol aortic valve surgery patients and the Monte Carlo-based generated Kaplan-Meier curve using.

Baseline characteristics of patients

Kaplan-Meier survival curves comparing survival between both time periods according to management strategy. Survival in patients with infective endocarditis.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Prakash Harikrishnan et al. JACEP 2015;1:

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p

Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.

Anemia as a risk factor for cardiovascular disease

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Meta-analysis of repeat revascularisation in randomised trials.

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Collet JP, et al. Lancet 2009;373:309-17

A Kaplan-Meier curve showing the cumulative incidence of the secondary NFE of TLR or de novo PCI during the 5-year follow-up (30 patients) (A) A heat map.

Kaplan-Meier analysis for the MACE-free or VA-free survival in patients with definite CS (A and C) or suspected CS (B and D) stratified by localisation.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

(A) Primary cardiovascular outcome: risk of major adverse cardiovascular effects (MACE) between triple antiplatelet therapy (TAPT) versus dual antiplatelet.

Forest plots of randomised controlled trials and propensity score matched studies examining outcomes between patients taking proton pump inhibitor (PPIs)

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Absolute ST segment elevation at the beginning of the primary percutaneous coronary intervention procedure (A), after guidewire passage (B), after thrombus.

Kaplan–Meier survival curve for major adverse cardiac events (MACE): a trend towards superior survival in patients without signs of coronary artery disease.

(A) Mortality in patients with heart failure and different estimated glomerular filtration rate (eGFR) strata, crude survival assessed by Kaplan-Meier.

Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.

Cumulative survival without events during 1 year of follow-up in patients treated with zofenopril (n=1808), placebo (n=951), lisinopril (n=520) or ramipril.

Perioperative associates of exaggerated heart rate responses pre-exercise. Perioperative associates of exaggerated heart rate responses pre-exercise. (A)

Associations between atmospheric chemistry transport model pollution concentrations at lags 0, 1 and 2 and myocardial infarction (% change in risk per.

Kaplan-Meier curve of cumulative percentage of cardiac mortality by peak flow rate category (adjusted HRs (95% CI) compared with ≥550 L/min: (

Correlation of calibrated integrated backscatter (cIB) with log10 total fibrosis (A) and log10 interstitial fibrosis (B) in patients undergoing coronary.

Kaplan–Meier plots of 5 and 12-year all cause (A and C, respectively) and cardiovascular mortality (B and D, respectively) with number of participants.

A: Kaplan-Meier curves depicting the cumulative probability of CVE in patients with low (

Kaplan-Meier survival curves for non-fatal stroke or mortality based on IMRS categories among (A) women (p-trend

Comparison of outcomes in patients with versus patients without diabetes; primary outcome event rate (CV death, non-fatal MI and non-fatal CVA) as a percentage.

Assessment of infarct size by biomarker measurement.

Any, acute and subacute stent thrombosis with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction.

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly ST segment elevation myocardial infarction (STEMI) studies; (A) glycoprotein.

Kaplan-Meier survival estimates for major cardiovascular events.

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Comparison of survival in patients with BAV (A) and TAV (B) in the US cohort using Kaplan-Meier curves, stratified by whether or not they had suffered.

Cardiac death, target vessel myocardial infarction (MI), target lesion revascularisation (TLR) by Kaplan-Meier method. Cardiac death, target vessel myocardial.

A: Incidences of all-cause mortality, coronary artery events, and cerebrovascular events by quartiles of baPWV during the follow-up period. A: Incidences.

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

Kaplan-Meier survival analysis for all-cause and CVD mortality in 2,823 type 2 diabetic patients stratified by CKD according to each creatinine-based equation.

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test

Survival curves according to the presence of late gadolinium enhancement (LGE) and elevated high-sensitivity C reactive protein (hs-CRP). Survival curves.

Kaplan-Meier analysis for the cumulative percentage of patients who remained hospitalized according to presence or absence of ARF with or without other.

Kaplan-Meier curves of ventricular arrhythmia–related events (A), death from MI (B), or both end points combined (C). Kaplan-Meier curves of ventricular.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

Kaplan-Meier survival curves for canine patients with (n = 3; huTyr Ab+) and without (n = 6; huTyr Ab-) positive humoral responses to the xenogeneic huTyr.

Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

Kaplan-Meier survival curves of the IMRS association with non-fatal stroke/mortality (stroke-free survival) in women with AF, stratified by CHA2DS2-VASc.

Kaplan-Meier estimates of all-cause mortality at 30 days.

Kaplan-Meier plot for the prespecified primary endpoint (CARE-HF (A) and the secondary composite endpoint (all-cause mortality and new onset heart failure.

Distribution of left atrial (LA) remodel.

Mortality rate according to our integrated index that combines DH and exercise capacity. Mortality rate according to our integrated index that combines.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

(A). (A). Kaplan-Meier plot of event-free survival in 27 LMNA mutation carriers and 78 DCM control patients. Death, heart transplantation, resuscitation.

Kaplan-Meier curve of the primary outcome in patients prescribed ACE inhibitor (ACEI) and angiotensin receptor blocker (ARB). Kaplan-Meier curve of the.

(A) Kaplan-Meier estimates of MACCE in patients with a non-culprit MaxLCBI4mm ≥400 and MaxLCBI4mm

Kaplan-Meier curves showing the probability of symptom-free survival according to the rate of heart rate rise during exercise testing in (A) for the whole.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation. Kaplan-Meier curves for the end point all-cause mortality in the total patient population stratified according to complete/incomplete revascularisation. Patients with incomplete revascularisation had a statistically significant higher cumulative incidence of all-cause mortality (p (log-rank)<0.001) during long-term follow-up after ST-segment elevation myocardial infarction in comparison with patients with complete revascularisation. Aukelien C Dimitriu-Leen et al. Open Heart 2017;4:e000541 ©2017 by British Cardiovascular Society